Chen Hongming 4
4 · Kala Pharmaceuticals, Inc. · Filed Jun 29, 2021
Insider Transaction Report
Form 4
Chen Hongming
Chief Scientific Officer10% Owner
Transactions
- Sale
Common Stock
2021-06-28$5.77/sh−2,452$14,148→ 240,563 total
Footnotes (2)
- [F1]This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.
- [F2]Includes 91,666 unvested RSUs.